BioWorld

June 23, 2010

View Archived Issues

Regulus Inks $750M Pre-Target miRNA Deal with Sanofi-Aventis

Regulus Therapeutics Inc. landed its biggest partnership to date: a $750 million deal with Sanofi-Aventis Group SA aimed at discovering microRNA-based drugs against four fibrosis targets. (BioWorld Today) Read More

Diamyd Climbs on $625M Type I Diabetes Deal with Ortho-McNeil

Read More

Metabolex, J&J Unit Sign $330M Deal for Type II Diabetes Drugs

Read More

Cadence 'Incline'd Toward Pain Market in Late-Stage Option Deal

Read More

Corrections & Clarifications

Read More

Other News To Note

Read More

Stock Movers

Read More

Clinic Roundup

Read More

Financings Roundup

Read More